Covered recipient · General Payments record
DANIEL D TRUONG
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$14,078.06
355 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $6,946.00 | 6 |
| Food and Beverage | $4,679.65 | 329 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,452.41 | 20 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 5 of 8; records 201–250 of 355 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DANIEL D TRUONG
NPI 1992720916 · CMS profile ID 44605
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
FOUNTAIN VALLEY, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 8; records 201–250 of 355 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1992720916?year=2021&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DANIEL D TRUONG, NPI 1992720916, CMS profile ID 44605. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 8; records 201–250 of 355 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992720916?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DANIEL D TRUONG, NPI 1992720916, CMS profile ID 44605. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 8; records 201–250 of 355 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992720916?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DANIEL D TRUONG, NPI 1992720916, CMS profile ID 44605, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 8; records 201–250 of 355 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1992720916?year=2021&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
355 matching records · $14,078.06 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 355.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $18.22 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839433495 | CMS |
| Acorda Therapeutics, Inc | $23.73 | 06/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792557707 | CMS |
| Neurocrine Biosciences, Inc. | $19.42 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837820177 | CMS |
| Novartis Pharmaceuticals Corporation | $8.41 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813323427 | CMS |
| AbbVie Inc. | $12.72 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796175057 | CMS |
| Sunovion Pharmaceuticals Inc. | $8.05 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821907787 | CMS |
| Allergan, Inc. | $16.24 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792970235 | CMS |
| Acorda Therapeutics, Inc | $5.40 | 06/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792557705 | CMS |
| Biogen, Inc. | $15.25 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827830485 | CMS |
| AbbVie Inc. | $10.54 | 06/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796175055 | CMS |
| Biohaven Pharmaceuticals, Inc. | $18.03 | 06/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852644831 | CMS |
| MDD US Operations, LLC | $16.36 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853059557 | CMS |
| Amneal Pharmaceuticals LLC | $19.43 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829682911 | CMS |
| Teva Pharmaceuticals USA, Inc. | $19.52 | 05/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839433493 | CMS |
| Allergan, Inc. | $16.09 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792970233 | CMS |
| Merz Pharmaceuticals, LLC | $8.32 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845432151 | CMS |
| Neurocrine Biosciences, Inc. | $17.22 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837820175 | CMS |
| ACADIA Pharmaceuticals Inc | $14.67 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838023321 | CMS |
| Sunovion Pharmaceuticals Inc. | $16.77 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821761243 | CMS |
| SK Life Science, Inc. | $19.94 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826842977 | CMS |
| Acorda Therapeutics, Inc | $17.47 | 05/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792557703 | CMS |
| MDD US Operations, LLC | $4.19 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853059555 | CMS |
| Novartis Pharmaceuticals Corporation | $13.61 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813323423 | CMS |
| Kyowa Kirin, Inc. | $15.68 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852993041 | CMS |
| Sunovion Pharmaceuticals Inc. | $22.44 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821945495 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.84 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829791885 | CMS |
| BANNER LIFE SCIENCES, LLC | $13.69 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843737467 | CMS |
| AbbVie Inc. | $19.11 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796175053 | CMS |
| Sunovion Pharmaceuticals Inc. | $9.64 | 05/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821896101 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.26 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839433491 | CMS |
| Neurocrine Biosciences, Inc. | $17.45 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837820173 | CMS |
| Allergan, Inc. | $16.24 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792970231 | CMS |
| Novartis Pharmaceuticals Corporation | $5.11 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813323419 | CMS |
| Acorda Therapeutics, Inc | $5.64 | 05/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792557701 | CMS |
| Eisai Inc. | $17.15 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817925003 | CMS |
| ACADIA Pharmaceuticals Inc | $27.53 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838023317 | CMS |
| Merz Pharmaceuticals, LLC | $16.44 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845432153 | CMS |
| Sunovion Pharmaceuticals Inc. | $8.62 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821903931 | CMS |
| Allergan, Inc. | $4.10 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792970229 | CMS |
| Amneal Pharmaceuticals LLC | $19.09 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829682907 | CMS |
| Biohaven Pharmaceuticals, Inc. | $6.17 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852644829 | CMS |
| Biogen, Inc. | $15.29 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827830483 | CMS |
| Merz Pharmaceuticals, LLC | $6.43 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845432145 | CMS |
| Amneal Pharmaceuticals LLC | $1,000.00 | 04/30/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829682903 | CMS |
| Neurocrine Biosciences, Inc. | $19.16 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837820171 | CMS |
| Sunovion Pharmaceuticals Inc. | $16.66 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821764921 | CMS |
| MDD US Operations, LLC | $1.25 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853059553 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $12.06 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820309683 | CMS |
| Novartis Pharmaceuticals Corporation | $12.80 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813323415 | CMS |
| UCB, Inc. | $15.45 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807339729 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $185,331.50 | 34 |
| PY2024 | Principal investigator | $182,774.45 | 36 |
| PY2023 | Recipient | $4,774.99 | 1 |
| PY2023 | Principal investigator | $263,413.84 | 103 |
| PY2022 | Principal investigator | $184,870.52 | 51 |
| PY2021 | Principal investigator | $110,461.25 | 31 |
| PY2020 | Principal investigator | $29,895.12 | 7 |
| PY2019 | Recipient | $6,548.80 | 4 |
| PY2019 | Principal investigator | $78,176.03 | 34 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
34 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ipsen Innovation | $4,732.28 | 10/27/2025 | Non-covered Recipient Entity Parkinsons And Movement Disorder Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184289434 |
| Principal investigator 1 | Ipsen Innovation | $4,247.60 | 10/27/2025 | Non-covered Recipient Entity Parkinsons And Movement Disorder Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184289436 |
| Principal investigator 1 | Ipsen Innovation | $5,409.88 | 10/27/2025 | Non-covered Recipient Entity Parkinsons And Movement Disorder Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184289438 |
| Principal investigator 1 | H. Lundbeck A S | $3,702.60 | 09/04/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251774261 |
| Principal investigator 1 | H. Lundbeck A S | $1,851.30 | 08/26/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251773958 |
| Principal investigator 1 | Ipsen Innovation | $15,000.00 | 08/06/2025 | Non-covered Recipient Entity Parkinsons And Movement Disorder Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184289430 |
| Principal investigator 1 | Ipsen Innovation | $2,500.00 | 08/04/2025 | Non-covered Recipient Entity Parkinsons And Movement Disorder Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184289432 |
| Principal investigator 1 | H. Lundbeck A S | $1,851.30 | 07/31/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251772902 |
| Principal investigator 1 | Ipsen Innovation | $43.50 | 07/21/2025 | Non-covered Recipient Entity The Truong Neuroscience Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184289254 |
| Principal investigator 1 | H. Lundbeck A S | $2,158.15 | 07/17/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251772394 |
| Principal investigator 1 | H. Lundbeck A S | $2,158.15 | 07/10/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251772064 |
| Principal investigator 1 | H. Lundbeck A S | $1,851.30 | 06/24/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251771491 |
| Principal investigator 1 | ABBVIE INC. | $485.00 | 06/05/2025 | Non-covered Recipient Entity PARKINSONS AND MOVEMENT DISORDER INSTITUTE | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202490577 |
| Principal investigator 1 | H. Lundbeck A S | $1,851.30 | 06/05/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251770688 |
| Principal investigator 1 | H. Lundbeck A S | $1,851.30 | 05/27/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251770645 |
| Principal investigator 1 | H. Lundbeck A S | $1,851.30 | 05/22/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251770580 |
| Principal investigator 1 | H. Lundbeck A S | $5,438.30 | 04/15/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251769665 |
| Principal investigator 1 | UCB SA | $9,433.77 | 04/14/2025 | Non-covered Recipient Entity PARKINSONS DIS AND MOVEMENT DISORDER INSTITUTE INC | A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease | No dispute reported | 06/30/2026 | 1246659416 |
| Principal investigator 1 | Ipsen Innovation | $3,733.13 | 04/04/2025 | Non-covered Recipient Entity Parkinsons And Movement Disorder Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184289440 |
| Principal investigator 1 | Sage Therapeutics, LLC | $27,634.00 | 04/04/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | Study to Evaluate SAGE-324 in Participants With Essential Tremors | No dispute reported | 06/30/2026 | 1206580885 |
| Principal investigator 1 | H. Lundbeck A S | $2,160.00 | 03/14/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251768757 |
| Principal investigator 1 | H. Lundbeck A S | $648.00 | 03/14/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251768760 |
| Principal investigator 1 | H. Lundbeck A S | $3,702.60 | 03/11/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251768626 |
| Principal investigator 1 | ABBVIE INC. | $260.34 | 02/27/2025 | Non-covered Recipient Entity PARKINSONS AND MOVEMENT DISORDER INSTITUTE | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | No dispute reported | 06/30/2026 | 1202455005 |
| Principal investigator 1 | ABBVIE INC. | $290.00 | 02/06/2025 | Non-covered Recipient Entity PARKINSONS AND MOVEMENT DISORDER INSTITUTE | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | No dispute reported | 06/30/2026 | 1202450070 |
| Principal investigator 1 | H. Lundbeck A S | $2,160.00 | 02/06/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251767153 |
| Principal investigator 1 | H. Lundbeck A S | $648.00 | 02/06/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251767157 |
| Principal investigator 1 | H. Lundbeck A S | $3,702.60 | 02/05/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251767027 |
| Principal investigator 1 | H. Lundbeck A S | $2,160.00 | 01/17/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251766566 |
| Principal investigator 1 | H. Lundbeck A S | $648.00 | 01/17/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251766569 |
| Principal investigator 1 | H. Lundbeck A S | $15,765.80 | 01/15/2025 | Non-covered Recipient Entity THE PARKINSONS AND MOVEMENT DISORDER INSTITUTE | AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | No dispute reported | 06/30/2026 | 1251766535 |
| Principal investigator 1 | UCB SA | $9,690.00 | 01/15/2025 | Non-covered Recipient Entity PARKINSON'S & MOVEMENT DISORDERS INSTITUTE | A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease | No dispute reported | 06/30/2026 | 1246657482 |
| Principal investigator 1 | UCB SA | $1,200.00 | 01/09/2025 | Non-covered Recipient Entity PARKINSONS DIS AND MOVEMENT DISORDER INSTITUTE INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246658540 |
| Principal investigator 1 | UCB SA | $44,512.00 | 01/07/2025 | Non-covered Recipient Entity PARKINSONS DIS AND MOVEMENT DISORDER INSTITUTE INC | A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246658762 |